RxDoctor Payments DataLook up a doctor →

Ramy Hanna, MD

Nephrology · Orange, CANPI 1518150283

Payments from drug & device makers

$922,760in general payments, 2019–2025

Across 509 payments — averaging $1812.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$483K
  • Novartis$144K
  • Apellis Pharmaceuticals, Inc.$86K
  • Aurinia Pharma U.S., Inc.$72K
  • Calliditas Therapeutics US Inc.$46K
  • Genentech, Inc.$37K
  • plus $55K from 17 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$922,760 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$251,306
Medicare patients
495
Services billed
1,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →